Test Code RSCOC Coccidioides Antibody Reflex, Complement Fixation and Immunodiffusion, Serum
Reporting Name
Coccidioides Ab, CompF/ImmDiff,SSpecimen Type
SerumOrdering Guidance
Specimen Required
Only orderable as a reflex. For more information see COXIS / Coccidioides Antibody Screen with Reflex, Serum.
Specimen Minimum Volume
1.2 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum | Refrigerated (preferred) | 14 days | |
Frozen | 14 days |
Reject Due To
All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.Reference Values
Only orderable as a reflex. For more information see COXIS / Coccidioides Antibody Screen with Reflex, Serum.
COMPLEMENT FIXATION:
Negative
If positive, results are titered.
IMMUNODIFFUSION:
Negative
Results are reported as positive, negative, or equivocal.
Performing Laboratory
Mayo Clinic Laboratories in RochesterTest Classification
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.CPT Code Information
86635 x 3
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
RSCOC | Coccidioides Ab, CompF/ImmDiff,S | 26625-4 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
35942 | Coccidioides Ab, CompF,S | 33379-9 |
35943 | Coccidioides, IgG, ImmDiff,S | 46182-2 |
35944 | Coccidioides, IgM, ImmDiff,S | 46183-0 |
Method Name
Only orderable as a reflex. For more information see COXIS / Coccidioides Antibody Screen with Reflex, Serum.
Complement Fixation (CF)/Immunodiffusion (ID)
Useful For
Detection of antibodies to Coccidioides species
Clinical Information
Coccidioidomycosis (valley fever, San Joaquin Valley fever) is a fungal infection found in the Southwestern US, Central America, and South America. It is acquired by inhalation of arthroconidia of Coccidioides immitis/posadasii. Usually, it is a mild, self-limiting pulmonary infection. Less commonly, chronic pneumonia may occur, progressing to fibronodular, cavitary disease. A rash often develops within a day or 2, followed by erythema nodosum or multiforme and accompanying arthralgias. About 2 weeks after exposure, symptomatic patients develop fever, cough, malaise, and anorexia; chest pain is often severe. Coccidioidomycosis may disseminate beyond the lungs to involve multiple organs, including the meninges.
IgG antibody is detected by the complement-fixation tests. Precipitating antibodies (IgM and IgG) are detected by immunodiffusion. They are rarely found in cerebrospinal fluid; however, their presence is associated with meningitis. Chronic coccidioidal pulmonary cavities are often accompanied by IgG and IgM precipitating antibodies.
Serologic testing for coccidioidomycosis should be considered when patients exhibit symptoms of pulmonary or meningeal infection and have lived or traveled in areas where Coccidioides immitis/posadasii is endemic. Any history of exposure to the organism or travel cannot be overemphasized when a diagnosis of coccidioidomycosis is being considered.
Interpretation
Complement Fixation:
Titer results of 1:2 or higher may suggest active disease; however, titers may persist for months after infection has resolved. Increasing complement fixation (CF) titer results in serial specimens are considered diagnostic of active disease.
Immunodiffusion:
The presence of IgM antibody may be detectable within 2 weeks after the onset of symptoms; however, antibody may be detected longer than 6 months after infection.
The presence of IgG antibody parallels the CF antibody and may suggest an active or a recent asymptomatic infection with Coccidioides immitis/posadasii; however, antibodies may persist after the infection has resolved.
An equivocal result (a band of nonidentity) cannot be interpreted as significant for a specific diagnosis. However, this may be an indication that a patient should be followed serologically.
Over 90% of primary symptomatic cases will be detected by combined immunodiffusion (ID) and CF testing.
Day(s) Performed
Monday through Friday